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CLINICAL PRESENTATION AND DIAGNOSIS
Malignant melanoma is a tumour that arises from pigmented cells,
the melanocytes. The majority of tumours present as pigmented
lesions in the skin and are known as cutaneous malignant
melanoma (CMM). Any part of the integument may be involved,
and the distribution varies according to gender and race (Cress
and Holly, 1997) with the most common presentation being on the
trunk for men and the lower limbs for women. According to recent
data (Rachet et al, 2008) there is an ongoing shift towards trunk
melanomas for both genders in the United Kingdom. Melanoma
can occur in any age group. Mortality rates peak in people aged
60–74 years but 15% of melanoma deaths occur in people aged
less than 50 years (Cancer Research UK, 2008). Childhood
melanoma is exceptionally rare.
The main tools used to assess the likelihood of a cutaneous
lesion representing a melanoma are the Glasgow seven point
checklist and the American ABCD system (McGovern and Litaker,
1992). The transition from benign naevus to melanoma was first
described by Clark (Clark et al, 1984). The genetic events that have
a function in the development of melanoma are increasingly
understood (Miller and Mihm, 2006) and this understanding is now
also feeding into the development of novel therapeutic strategies. As
in other tumours, hereditary genetic characteristics can have an
important function in the pathogenesis of melanoma. This is
illustrated by the observation that in melanoma families a substantial
proportion carry mutations in the CDKN2A tumour suppressor gene
(Flores et al, 1997; Platz et al, 1997; Lang et al, 2005).
Critical risk factors for developing CMM include phenotypic
factors, in particular skin type (Tsao et al, 2004), which affects the
risk conferred by environmental exposure to solar radiation
(Whiteman et al, 2006). The link between tanning and risk for
melanoma lies in polymorphisms in the MC1R (melanocortin
receptor 1) gene, which impair the tanning response to UV light
(Miller and Mihm, 2006). Unsurprisingly any individual who has
had a melanoma in the past is at increased risk of developing a
second primary melanoma. However UV-induced damage is not
an absolute requirement for the genesis of melanoma, as
melanoma can arise in a wide range of internal organs, including
mucosal sites and visceral locations (Thoelke et al, 2004). The
incidence of noncutaneous melanomas (NCMM) is not as well
characterized as for cutaneous primaries, with the exception of
ocular melanomas (Damato, 2006). The overall frequency is
approximately 5% of all melanomas and work is ongoing to define
both the incidence and outcomes of NCMM.
The mainstay of diagnosis in CMM is clinical assessment by an
experienced dermatologist, followed by an excision biopsy.
Histological assessment may be supplemented by immunohisto-
chemistry for antigens such as S100 and HMB45. S100 belongs to
the family of calcium binding proteins and can be detected in
almost all benign naevi and malignant melanocytic tumours of the
skin, as well as in Langerhans cells in the skin. HMB45 reacts with
a neuraminidase-sensitive oligosaccharide side chain of a glyco-
conjugate, which is present in immature melanosomes and
cutaneous melanocytes.
There is a close association between the thickness of the tumour
in millimetres and outlook, and this is reflected in the current
AJCC staging system (Balch et al, 2001). The prognosis for the
majority of patients with thin tumours o1mm is excellent,
however, the outlook rapidly worsens as tumours become thicker.
Additional adverse features include ulceration of the primary, high
mitotic index and invasion of vessels. Ulceration is incorporated
into the AJCC staging system. Education of the population in
relation to awareness of the risk factors for melanoma, has an
important function in prevention and there are data that show this
can indeed be beneficial (MacKie et al, 2003). A recent advance has
been the detection of early lymph node involvement by sentinel
node biopsy (SNB). There is no doubt that this staging method
picks up stage III patients early (Johnson et al, 2006; Kettlewell
et al, 2006) and leads to stage migration of patients with better
prognosis for stage III disease who were regarded as having stage II
disease earlier. There is a resultant improvement in survival for
both groups. Whether the procedure itself confers a survival
advantage and more importantly, whether patients with positive
SNB nodes should be offered aggressive surgical management with
block dissections remains uncertain. This latter question is the
subject of the ongoing large multicenter and multinational MLST
II trial.
TREATMENT AND OUTLOOK
The mainstay of treatment for melanoma, CMM or NCMM,
remains surgery. Guidelines for width of surgical excision of CMM
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locally advanced or metastatic disease, palliative radiotherapy can
be used. For a few highly selected patients isolated limb perfusion
using melphalan without or with tumour necrosis factor can offer
local control (Grunhagen et al, 2006). No significant progress has
been made for the treatment of metastatic disease, where
dacarbazine remains a poorly effective standard of care. Multi-
agent chemotherapy without or with biological response modifiers
has shown higher response rates but has not impacted survival
(Eggermont, 2006).
A great deal of work has been undertaken in the area of
immunotherapy. To date, the results have been disappointing,
perhaps because of a lack of understanding of the underlying
mechanisms that confer resistance to immunologically based
therapies. The most convincing evidence that supports the use of
immunotherapeutic strategies comes from data on transfer of
autologous tumour infiltrating T cells, although benefit has only
been shown in a small number of highly selected patients (Dudley
and Rosenberg, 2003). Nevertheless this approach demonstrates
the potential effectiveness of immunotherapy and other rational
strategies are under investigation, which capitalise on our
improved understanding of the tumour immunology in other
solid tumours and infectious diseases. Recently anti-CTLA4
antibodies, which are potent activators of immune responses,
have been combined with vaccines and this approach may deliver a
real improvement in the treatment of advanced disease. However it
is also clear that such strategies come at a cost, with significant
side effects being common (Beck et al, 2006).
In parallel to the use of tyrosine kinase inhibitors in other
tumours, in particular renal cell carcinomas, these agents are
undergoing investigation in phase III studies in patients with
melanoma. Sorafinib mainly targets BRAF but it is also a
multitargeting agent. On its own it appears to be of limited clinical
use, however combinations with chemotherapy and anti-vascular
agents are being explored (Strumberg, 2005). Similarly monoclonal
antibody therapies are being explored in melanoma and other solid
tumours (reviewed in Adams and Weiner, 2005). Antiangiogenic
agents are likely to be a substantial area of investigation in the
coming years (reviewed in Jain et al, 2006). For instance,
Bevacizumab, which confers a survival advantage in colorectal
cancer (Meyerhardt and Mayer, 2005) is about to be evaluated in
melanoma in the adjuvant setting in the United Kingdom. Even now
the role of interferon in the adjuvant setting remains to be defined.
While a small survival benefit has become apparent, both dose and
duration of treatment with interferon remain uncertain. An
interesting new strategy is to target adhesion molecules, such as
a-integrins and two such antibodies have recently entered clinical
trials. A very different approach is provided by the use of statins
either for chemoprevention or in combination with chemotherapy
(reviewed in Demierre et al, 2005).
Currently, patients with high risk primaries or advanced disease
should be offered entry into clinical trials as these are crucial for
the identification of promising new strategies in the management
of this disease. This research effort will be facilitated by the
multidisciplinary team reviews that take place for all patients with
malignancy.
INTERPRETATION OF SURVIVAL PATTERNS
AGAINST THIS CLINICAL BACKGROUND
The analysis by Rachet et al (2008) in this journal shows that as in
other countries (Micheli et al, 2002) the rate of incidence of
cutaneous melanoma in the United Kingdom is rising more steeply
than for most other cancers. This may be related to an increasingly
affluent population, which is more frequently exposed to inter-
mittent UV radiation. There also appears to be a narrowing of the
deprivation gap in melanoma survival in the United Kingdom and
it is likely that the increased awareness of melanoma as a lethal
disease is because of this. Increased awareness also results in the
detection of thinner tumours with a more favourable outcome
(MacKie et al, 2003). This explanation is likely, as current
treatments have not had a significant impact on either preventing
or treating advanced disease. Unless the new treatments currently
undergoing clinical investigation show a benefit for thicker, node
positive or metastatic tumours, the most important impact on
survival from melanoma will be derived from further education
and prevention campaigns for the foreseeable future. One example
for this is the SunSmart campaign (http://info.cancerresearchuk.org/
healthyliving/sunsmart/) funded by Cancer Research, United King-
dom and the departments of health, and such initiatives should be
supported and expanded.
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